Innovative Pipeline
We are commercializing INPEFA® (sotagliflozin) for the treatment of heart failure. We have also advanced multiple other drug candidates into late-stage clinical development and continue to advance additional drug candidates from our discovery platform.
We are one of a relatively small number of companies to have advanced a drug all the way from discovery in our own laboratories to market.
Drug candidate / area of study - Heart Failure
Target - SGLT2/SGLT1
Status - Approved May 26, 2023
Drug candidate / area of study - Diabetic Peripheral Neuropathic Pain (DPNP)
Target - AAK1
Status - Wholly Owned*
* Subject to milestone and royalty obligations to Bristol-Myers Squibb
Drug candidate / area of study - Type 1 Diabetes
Target - SGLT2/SGLT1
Status - Wholly Owned
US CRL - Ongoing Regulatory Engagement
Drug candidate / area of study - Hypertrophic Cardiomyopathy (HCM)
Target - SGLT2/SGLT1
Status - Wholly Owned
Drug candidate / area of study - Obesity
Status - Wholly Owned
Milestone / Royalty Rights
We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs. Consistent with this approach, we seek to retain exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.
We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may provide us with access to expertise and resources that we do not possess internally or are complementary to our own.
We also seek to collaborate with other pharmaceutical and biotechnology companies, research institutes and academic institutions to capitalize on our drug target discoveries.
Explore our Products
See Products
